glp 1 and sglt2 Renal outcomes of inhibitors GLP1 agonists in clinical practice Real-World Evidence for GLP-1 Receptor

10.1111/dom.13380

There are certain medical histories and conditions where GLP-1 medications may not be recommended

One drug class that has garnered interest in the management of neuro-ophthalmic conditions is glucagon-like peptide 1 receptor agonists (GLP-1RAs)

Tirzepatide functions as both a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist

This review focuses on synthesized Semaglutide therapy impact in obesity (STEP) trials

Findings GLP-1 RAs exhibit potential beneficial effects on depressive symptoms, cognitive function, and reduced risk of suicidal ideation in animal and human models through antioxidative, anti-inflammatory mechanisms, and modulation of neurotransmitter pathways